<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00662870</url>
  </required_header>
  <id_info>
    <org_study_id>P3T06</org_study_id>
    <nct_id>NCT00662870</nct_id>
  </id_info>
  <brief_title>Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended Vaccine</brief_title>
  <official_title>Safety, Immunogenicity and Lot Comparability of DAPTACEL™ (Aventis Pasteur Classic Five-component Pertussis Vaccine in Combination With Tetanus and Diphtheria Toxoids Adsorbed) When Administered With Other Recommended Vaccines at 2, 4, 6, and 15 to 16 Months of Age.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to assess the lot comparability of DAPTACEL, as well as the safety
      and immunogenicity of DAPTACEL when co-administered with other recommended infant vaccines.

      Stage I Primary Objectives:

        1. To assess the lot-comparability of immunogenicity of DAPTACEL by when co-administered
           with other recommended vaccines.

        2. To compare the immune response to DTaP-IPV/Hib (Pentacel) with those of three lots of
           DAPTACEL when co-administered with other recommended vaccines.

        3. To compare the immune response of PRP-T antigen in Pentacel with that of ActHIB
           concurrently administered in a different injection site with DAPTACEL when these
           vaccines are co-administered with other recommended vaccines.

      Stage II Primary Objectives:

        1. To compare the immune response of DAPTACEL when the 4th dose is co-administered with Hib
           or other infant vaccines.

        2. To compare the the immune response of Pentacel with those elicited by DAPTACEL when
           co-administered with ActHIB in toddlers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a two-stage, randomized, multi-center study to assess the safety, immunogenicity and
      lot comparability of DAPTACEL
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2001</start_date>
  <completion_date type="Actual">January 2004</completion_date>
  <primary_completion_date type="Actual">January 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity: To provide information concerning the immune response of DAPTACEL after vaccination.</measure>
    <time_frame>30 days post-vaccination 3</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1941</enrollment>
  <condition>Diphtheria</condition>
  <condition>Tetanus</condition>
  <condition>Whooping Cough</condition>
  <condition>Polio</condition>
  <condition>Haemophilus Influenzae Type b</condition>
  <arm_group>
    <arm_group_label>DAPTACEL Lot 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receiving Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine (DAPTACEL) Lot 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DAPTACEL Lot 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receiving Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine (DAPTACEL) Lot 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DAPTACEL Lot 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receiving Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine (DAPTACEL) Lot 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pentacel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receiving Pentacel vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine)</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>DAPTACEL Lot 1</arm_group_label>
    <arm_group_label>DAPTACEL Lot 2</arm_group_label>
    <arm_group_label>DAPTACEL Lot 3</arm_group_label>
    <other_name>DAPTACEL®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pentacel: DTaP-IPV/Hib</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Pentacel</arm_group_label>
    <other_name>Pentacel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :

          -  Healthy infants 2 months of age.

          -  Infants with at least 37 weeks of gestation at delivery.

          -  Signed informed consent from parent or guardian.

          -  Able to attend the scheduled visits and to comply with the study procedure.

          -  Subjects must have received the first dose of hepatitis B vaccine from birth to 28
             days prior to the first dose of DAPTACEL or Pentacel.

        Exclusion Criteria :

          -  Clinically significant findings on review of systems or physical examination
             (determined by investigator or sub-investigator to be sufficient for exclusion).

          -  Known or suspected hypersensitivity to any component of the study vaccine to be
             administered.

          -  Known or suspected impairment of immunologic function or receipt of immunosuppressive
             therapy or immunoglobulin since birth.

          -  Known HIV-positive mother.

          -  Personal or immediate family history of congenital immune deficiency.

          -  Developmental delay or neurologic disorders.

          -  Chronic medical, congenital, developmental or surgical disease.

          -  Participation in any other experimental vaccine trial.

          -  Any condition which, in the opinion of the investigator or sub-investigator, would
             interfere with the evaluation of the vaccine or pose a health risk to the subject.

          -  Prior history of having received more than one dose of hepatitis B vaccine, any
             diphtheria, tetanus and acellular pertussis combination vaccine (DTaP), diphtheria,
             tetanus and whole-cell pertussis combination vaccine (DTwP), Haemophilus influenzae
             type b (Hib)-conjugate vaccine, poliovirus vaccine or pneumococcal conjugate vaccine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>42 Days</minimum_age>
    <maximum_age>84 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Fayetteville, AR 72703</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jonesboro, AR 72401</city>
        <state>Arkansas</state>
        <zip>7240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Little Rock, AR 72211</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fountain Valley, CA 92708</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Englewood, CO 80112</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norwich, CT 06360</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando, FL 32856</city>
        <state>Florida</state>
        <zip>32856</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marietta, GA 30062</city>
        <state>Georgia</state>
        <zip>30062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago, IL 60614</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bardstown, KY 40004</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bossier City, LA 71111</city>
        <state>Louisiana</state>
        <zip>71111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bridgeton, MO 63044</city>
        <state>Missouri</state>
        <zip>63044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester, NY 14620</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chapel Hill, NC 27514</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland, OR 97201</city>
        <state>Oregon</state>
        <zip>97201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norristown, PA 19401</city>
        <state>Pennsylvania</state>
        <zip>19401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh, PA 15213</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh, PA 15241</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kingsport, TN 37664</city>
        <state>Tennessee</state>
        <zip>37664</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin, TX 78758</city>
        <state>Texas</state>
        <zip>78758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Worth, TX 76107</city>
        <state>Texas</state>
        <zip>76106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio, TX 78205</city>
        <state>Texas</state>
        <zip>78205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Provo, UT 84604</city>
        <state>Utah</state>
        <zip>84604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spokane, WA 99220</city>
        <state>Washington</state>
        <zip>99220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>LaCrosse, WI 54601</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marshfield, WI 54449</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofiaventis.com</url>
  </link>
  <results_reference>
    <citation>Guerra FA, Blatter MM, Greenberg DP, Pichichero M, Noriega FR; Pentacel Study Group. Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed equivalent vaccines in US infants and toddlers and persistence of antibodies before a preschool booster dose: a randomized, clinical trial. Pediatrics. 2009 Jan;123(1):301-12. doi: 10.1542/peds.2007-3317.</citation>
    <PMID>19117896</PMID>
  </results_reference>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2008</study_first_submitted>
  <study_first_submitted_qc>April 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2008</study_first_posted>
  <last_update_submitted>January 26, 2012</last_update_submitted>
  <last_update_submitted_qc>January 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DAPTACEL</keyword>
  <keyword>Diphtheria</keyword>
  <keyword>Tetanus</keyword>
  <keyword>Whooping Cough</keyword>
  <keyword>Polio</keyword>
  <keyword>Haemophilus influenzae type b</keyword>
  <keyword>Pertussis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Tetany</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Whooping Cough</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

